Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers

Kobayashi,Yu; Takano,Atsushi; Miyagi,Yohei; Tsuchiya,Eiju; Sonoda,Hiromichi; Shimizu,Tomoharu; Okabe,Hidetoshi; Tani,Toru; Fujiyama,Yoshihide; Daigo,Yataro

doi:10.3892/ijo.2013.2177

Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers

Authors:
- Yu Kobayashi
- Atsushi Takano
- Yohei Miyagi
- Eiju Tsuchiya
- Hiromichi Sonoda
- Tomoharu Shimizu
- Hidetoshi Okabe
- Toru Tani
- Yoshihide Fujiyama
- Yataro Daigo
View Affiliations

Affiliations: Department of Medical Oncology, Shiga University of Medical Science, Otsu, Japan, Kanagawa Cancer Center, Research Institute, Yokohama, Japan, Department of Surgery, Shiga University of Medical Science, Otsu, Japan, Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Otsu, Japan, Department of Medicine, Shiga University of Medical Science, Otsu, Japan
Published online on: November 15, 2013 https://doi.org/10.3892/ijo.2013.2177
Pages: 69-77

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To identify new cancer biomarkers and therapeutic targets for colorectal cancers (CRCs), we performed immunohistochemical analysis using tissue microarrays covering archival tumor tissue samples from 434 CRC patients and antibodies to cell division cycle-associated protein 1 (CDCA1) that was originally identified as an oncoantigen by our gene expression profile database, and compared its expression with several clinicopathological factors. Strong CDCA1 positivity was associated with poorer prognosis for patients with CRC (P=0.019) and multivariate analysis confirmed its independent prognostic value. In addition, transfection of siRNAs against CDCA1 suppressed its expression and induced apoptosis of CRC cells. These results suggest that CDCA1 could be a prognostic biomarker and a potential therapeutic target for CRCs.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
3.	Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 48:1466–1475. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Daigo Y and Nakamura Y: From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Daigo Y, Takano A, Teramoto K, Chung S and Nakamura Y: A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses. Clin Pharmacol Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
6.	Kikuchi T, Daigo Y, Katagiri T, et al: Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Kakiuchi S, Daigo Y, Ishikawa N, et al: Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Kikuchi T, Daigo Y, Ishikawa N, et al: Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol. 28:799–805. 2006.PubMed/NCBI
9.	Taniwaki M, Daigo Y, Ishikawa N, et al: Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
10.	Yamabuki T, Daigo Y, Kato T, et al: Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol. 28:1375–1384. 2006.PubMed/NCBI
11.	Suzuki C, Daigo Y, Kikuchi T, Katagiri T and Nakamura Y: Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 63:7038–7041. 2003.PubMed/NCBI
12.	Kato T, Daigo Y, Hayama S, et al: A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Furukawa C, Daigo Y, Ishikawa N, et al: Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res. 65:7102–7110. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Suzuki C, Daigo Y, Ishikawa N, et al: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Takahashi K, Furukawa C, Takano A, et al: The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Hayama S, Daigo Y, Kato T, et al: Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Kato T, Hayama S, Yamabuki T, et al: Increased expression of IGF-II mRNA-binding protein 1 is associated with the tumor progression in patients with lung cancer. Clin Cancer Res. 13:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Hayama S, Daigo Y, Yamabuki T, et al: Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Taniwaki M, Takano A, Ishikawa N, et al: Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Kato T, Sato N, Hayama S, et al: Activation of holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Kato T, Sato N, Takano A, et al: Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res. 14:2363–2370. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Dunleavy EM, Roche D, Tagami H, et al: HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell. 137:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Hirata D, Yamabuki T, Miki D, et al: Involvement of epithelial cell transforming sequence 2 (ECT2) oncoantigen in lung and esophageal cancer progression. Clin Cancer Res. 15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Sato N, Koinuma J, Fujita M, et al: Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 16:226–239. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Nguyen MH, Koinuma J, Ueda K, et al: Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Aragaki M, Takahashi K, Akiyama H, et al: Characterization of a cleavage stimulation factor, 3′ pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin Cancer Res. 7:5889–5900. 2011.
27.	Masuda K, Takano A, Oshita H, et al: Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 17:7712–7722. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Fujitomo T, Daigo Y, Matsuda K, Ueda K and Nakamura Y: Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis. Cancer Res. 72:4110–4118. 2012. View Article : Google Scholar : PubMed/NCBI
29.	Oshita H, Nishino R, Takano A, et al: RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer. Mol Cancer Res. 11:937–951. 2013. View Article : Google Scholar : PubMed/NCBI
30.	Ishikawa N, Daigo Y, Yasui W, et al: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Ishikawa N, Daigo Y, Takano A, et al: Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Yamabuki T, Takano A, Hayama S, et al: Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007. View Article : Google Scholar : PubMed/NCBI
33.	Ishikawa N, Takano A, Yasui W, et al: Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 67:11601–11611. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Takano A, Ishikawa N, Nishino R, et al: Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009. View Article : Google Scholar : PubMed/NCBI
35.	Sato N, Yamabuki T, Takano A, et al: Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 70:5326–5336. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Nishino R, Takano A, Oshita H, et al: Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 17:6272–6286. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Suda T, Tsunoda T, Daigo Y, Nakamura Y and Tahara H: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Mizukami Y, Kono K, Daigo Y, et al: Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 99:1448–1454. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Harao M, Hirata S, Irie A, et al: HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer. 123:2616–2625. 2008. View Article : Google Scholar : PubMed/NCBI
40.	Kono K, Mizukami Y, Daigo Y, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509. 2009. View Article : Google Scholar : PubMed/NCBI
41.	Yokomine K, Senju S, Nakatsura T, et al: The forkhead box M1 transcription factor, as a possible immunotherapeutic tumor-associated antigen. Int J Cancer. 126:2153–2163. 2010.
42.	Tomita Y, Imai K, Senju S, et al: A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells. Cancer Sci. 102:697–705. 2011. View Article : Google Scholar : PubMed/NCBI
43.	Kaneko N, Miura K, Gu Z, Karasawa H, Ohnuma S, Sasaki H, Tsukamoto N, Yokoyama S, Yamamura A, Nagase H, Shibata C, Sasaki I and Horii A: siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun. 390:1235–1240. 2009. View Article : Google Scholar : PubMed/NCBI
44.	van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS and Sonneveld P: Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 96:1662–1669. 2011.PubMed/NCBI
45.	DeLuca JG, Moree B, Hickey JM, Kilmartin JV and Salmon ED: hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol. 159:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
46.	DeLuca JG, Howell BJ, Canman JC, Hickey JM, Fang G and Salmon ED: Nuf2 and Hec1 are required for retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. Curr Biol. 13:2103–2109. 2003. View Article : Google Scholar : PubMed/NCBI
47.	Liu D, Ding X, Du J, Cai X, Huang Y, Ward T, Shaw A, Yang Y, Hu R, Jin C and Yao X: Human NUF2 interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment. J Biol Chem. 282:21415–21424. 2007. View Article : Google Scholar : PubMed/NCBI
48.	Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H and Okano Y: Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis. 4:e6032013. View Article : Google Scholar : PubMed/NCBI
49.	Keen N and Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004. View Article : Google Scholar : PubMed/NCBI
50.	Jang YJ, Kim YS and Kim WH: Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol. 29:589–594. 2006.PubMed/NCBI